These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Boulton-Jones JR, Pritchard K, Mahmoud AA. Aliment Pharmacol Ther; 2000 Dec; 14(12):1561-5. PubMed ID: 11121903 [Abstract] [Full Text] [Related]
25. Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids. Hradsky O, Copova I, Zarubova K, Nevoral J, Bronsky J. Dig Dis Sci; 2016 Jul; 61(7):2041-50. PubMed ID: 26971092 [Abstract] [Full Text] [Related]
26. [Inflammatory bowel disease. If a patient with Crohn's disease remains in remission for 4 years with azathioprine (or mercaptopurine), should the drug be withdrawn?]. García López S. Gastroenterol Hepatol; 2008 Dec; 31(10):704-5. PubMed ID: 19280773 [No Abstract] [Full Text] [Related]
27. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Modigliani R, Bouhnik Y, Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Gastroenterology; 2005 Jun; 128(7):1812-8. PubMed ID: 15940616 [Abstract] [Full Text] [Related]
28. Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance. Jacobstein DA, Baldassano RN. Inflamm Bowel Dis; 2005 Feb; 11(2):203-5. PubMed ID: 15677916 [No Abstract] [Full Text] [Related]
29. [Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases]. Lémann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC. Gastroenterol Clin Biol; 1990 Feb; 14(6-7):548-54. PubMed ID: 2397863 [Abstract] [Full Text] [Related]
30. Azathioprine and 6 Mercaptopurine in postoperative maintenance of Crohn's disease remission: is no evidence of effect an evidence of no effect? Mardini HE. Gastroenterology; 2005 Jan; 128(1):246-8; author reply 248-9. PubMed ID: 15633153 [No Abstract] [Full Text] [Related]
31. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Bonaz B, Boitard J, Marteau P, Lémann M, Coffin B, Flourié B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF, Getaid. Aliment Pharmacol Ther; 2003 Aug 15; 18(4):401-8. PubMed ID: 12940925 [Abstract] [Full Text] [Related]
32. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions. Soh JS, Yun WJ, Kim KJ, Won CH, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Kim JH. Inflamm Bowel Dis; 2015 Apr 15; 21(4):832-9. PubMed ID: 25789922 [Abstract] [Full Text] [Related]
33. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Kennedy NA, Rhatigan E, Arnott ID, Noble CL, Shand AG, Satsangi J, Lees CW. Aliment Pharmacol Ther; 2013 Nov 15; 38(10):1255-66. PubMed ID: 24117596 [Abstract] [Full Text] [Related]
34. Long-term prognosis of crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH. Inflamm Bowel Dis; 2014 Mar 15; 20(3):488-94. PubMed ID: 24412992 [Abstract] [Full Text] [Related]
35. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M, AZTEC Study Group. Gastroenterology; 2013 Oct 15; 145(4):766-74.e1. PubMed ID: 23770132 [Abstract] [Full Text] [Related]
36. Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con. Griffiths AM. Inflamm Bowel Dis; 2005 Feb 15; 11(2):200-2. PubMed ID: 15677915 [No Abstract] [Full Text] [Related]
37. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy. Kang B, Choi SY, Choi YO, Kim MJ, Kim K, Lee JH, Choe YH. J Crohns Colitis; 2018 May 25; 12(6):644-652. PubMed ID: 29474531 [Abstract] [Full Text] [Related]
38. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy. Balram B, Lubov J, Theoret Y, Afif W, Bitton A, Wild G, Lakatos PL, Bessissow T. Dig Dis Sci; 2021 May 25; 66(5):1650-1657. PubMed ID: 32591969 [Abstract] [Full Text] [Related]
39. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. O'Brien JJ, Bayless TM, Bayless JA. Gastroenterology; 1991 Jul 25; 101(1):39-46. PubMed ID: 2044925 [Abstract] [Full Text] [Related]
40. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. J Pediatr Gastroenterol Nutr; 1999 Jan 25; 28(1):54-8. PubMed ID: 9890469 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]